Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS (MEDICAID)

Antidepressants Non-Formulary (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at 1-855-684-5250.

When conditions are met, we will authorize the coverage of Antidepressants Non-Formulary (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name			
Please specify			
			_
Route of Administration			
Patient Information			
Patient Name:			
Patient ID:			
Patient DOB:			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		
Please circle the appropriate answer		_	
Is the patient currently ta	king this medication?	Υ	N
If yes, please specify how	w patient has been receiving medication		
(insurance, samples, pay	,		
[If no, then skip to questi	on 3.1		
	•	Υ	N
2. Is the patient responding to therapy with this medication?		•	11
[If yes, then skip to quest	tion18.]		
[If no, then no further que	estions.]		
3. Does the patient have M	ajor Depressive Disorder or Seasonal Affective	Υ	Ν

Disorder?

[If no, then skip to question 10.]

4.	Did the patient experience treatment failure or intolerable side effects with 3 antidepressants from at least 2 different classes (SSRI, SNRI, bupropion, or mirtazapine) at an adequate dose and duration (at least 4 weeks)?	Υ	N
	If yes, please list medications and doses tried:		
	[If yes, then skip to question 6.]		
5.	Did the patient experience treatment failure or intolerable side effects with trials of TWO different antidepressants AND an acceptable antidepressant augmentation regimen at an adequate dose and duration (at least 4 weeks)?	Υ	N
	Note: Acceptable augmentation regimens include an SSRI or SNRI plus one of the following: bupropion, lithium, atypical antipsychotic, buspirone, or liothyronine.		
	If yes, please list medications and doses tried:		
	[If no, then no further questions.]		
6.	Is the request for Trintellix or Viibryd?	Υ	N
	[If no, then skip to question 8.]		
7.	Was one of the antidepressant trials with a preferred formulary SSRI such as sertraline, citalopram, escitalopram, fluoxetine, or paroxetine?	Υ	N
	[If yes, then skip to question18.]		
	[If no, then no further questions.]		
8.	Is the request for Fetzima?	Υ	Ν
	[If no, then skip to question 16.]		
9.	Was one of the antidepressant trials with a preferred formulary SNRI such as venlafaxine or duloxetine?	Υ	N
	[If yes, then skip to question18.]		
	[If no, then no further questions.]		

Reference Number: C8021-A / Effective Date: 12/01/2017

10. Does the patient have Obsessive-Compulsive Disorder?	Υ	N
[If no, then skip to question 12.]		
11. Did the patient experience treatment failure or intolerable side effects with 3 other antidepressants (e.g., SSRI's, clomipramine) at an adequate dose and duration (at least 4 weeks)?	Y	N
If yes, please list medications and doses tried:		
[If yes, then skip to question 16.]		
[If no, then no further questions.]		
12. Does the patient have hot flashes associated with menopause?	Υ	Ν
[If no, then skip to question 14.]		
13. Did the patient experience treatment failure or intolerable side effects with, or has a clinical reason to avoid, hormonal therapy?	Υ	N
[If yes, then skip to question 15.]		
[If no, then no further questions.]		
14. Does the patient have Panic Disorder or Generalized Anxiety?	Y	N
[If no, then no further questions.]		
15. Did the patient experience treatment failure or intolerable side effects with 3 antidepressants from at least 2 different classes (SSRIs or SNRIs) at an adequate dose and duration (at least 4 weeks)?	Υ	N
If yes, please list medications and doses tried:		
[If no, then no further questions.]		
16. Is the request for Pexeva, Aplenzin, Forfivo XL, fluvoxamine ER, paroxetine mesylate capsule, fluoxetine weekly, venlafaxine SR tablets, or paroxetine ER?	Υ	N
[If no, then skip to question18.]		
17. Has the patient experience treatment failure or intolerable side effects with a formulary preferred product with the same active ingredient?	Υ	N
[If no, then no further questions.]		

Reference Number: C8021-A / Effective Date: 12/01/2017

manufacturer's published package labeling? If yes, provide dose and frequency and reason for exceeding the	· ·	IN
maximum dose or dosing frequency:		
Comments:		
I affirm that the information given on this form is true and accurate as of this date.		
Prescriber (Or Authorized) Signature Da	ate	

Reference Number: C8021-A / Effective Date: 12/01/2017